TNFRSF8 and neoplasm: Anti-CD30-LDM was radiolabeled with 123I and demonstrated strong binding capabilities in CD30-positive cells, and a biodistribution study showed a 2-fold higher tumor uptake in CD30+ versus CD30- tumors (4.98 ± 0.99%ID/g vs. 2.75 ± 0.47%ID/g, respectively) [175].